Skip to main content

Advertisement

Log in

Opioids and Chronic Pain: Where Is the Balance?

Current Oncology Reports Aims and scope Submit manuscript

Abstract

Chronic opioid therapy (defined as greater than 3 months on opioids) is a common practice for those with non-cancer pain, cancer survivors with treatment-related pain, and individuals with cancer undergoing disease-modifying therapy with a survival that can be for a year or more. Recent studies have found unique long-term toxicities with opioids which reduce the utility of opioid therapy in chronic pain. The risk of addiction, depression, central hypogonadism, sleep-disordered breathing, impaired wound healing, infections, cognitive impairment, falls, non-vertebral fractures, and mortality are increased in populations on long-term opioids. Factors associated with these risks are related to dose, duration of opioid therapy, type of opioid, and formula (long-acting, short-acting). This state-of-the-art review discusses the risks and benefits of chronic opioid therapy and strategies to increase utility and diminish risks to opioid therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Mularski RA, White-Chu F, Overbay D, Miller L, Asch SM, Ganzini L. Measuring pain as the 5th vital sign does not improve quality of pain management. J Gen Intern Med. 2006;21(6):607–12.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Toblin RL, Mack KA, Perveen G, Paulozzi LJ. A population-based survey of chronic pain and its treatment with prescription drugs. Pain. 2011;152(6):1249–55.

    Article  PubMed  Google Scholar 

  3. ••Lee TH. Zero pain is not the goal. Jama. 2016;315(15):1575–7. This is an important essay which clinicians should read to get a perspective on opioid therapy and patients.

    Article  PubMed  Google Scholar 

  4. Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559–74.

    Article  PubMed  Google Scholar 

  5. ••Ballantyne JC, Sullivan MD. Intensity of Chronic Pain. N Engl J Med. 2016;374(14):1395. This essay puts the use of pain intensity for chronic pain outcomes in a new light.

    Article  PubMed  Google Scholar 

  6. •Ballantyne JC, Kalso E, Stannard C. WHO analgesic ladder: a good concept gone astray. BMJ. 2016;352:i20. The WHO ananlgesic ladder was intended for advanced cancer pain is a dangerous strategy in managing chronic pain.

    Article  PubMed  Google Scholar 

  7. ••Chen L, Vo T, Seefeld L, Malarick C, Houghton M, Ahmed S, et al. Lack of correlation between opioid dose adjustment and pain score change in a group of chronic pain patients. J Pain. 2013;14(4):384–92. Patients with chronic pain on chronic opioid therapy do not improve with dose escalation or worsen with dose reduction.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Naliboff BD, Wu SM, Schieffer B, Bolus R, Pham Q, Baria A, et al. A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain. J Pain. 2011;12(2):288–96.

    Article  CAS  PubMed  Google Scholar 

  9. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. Jama. 2016;315(15):1624–45.

    Article  CAS  PubMed  Google Scholar 

  10. Ballantyne JC. Avoiding opioid analgesics for treatment of chronic low back pain. Jama. 2016;315(22):2459–60.

    Article  CAS  PubMed  Google Scholar 

  11. Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use. Spine. 2007;32(19):2127–32.

    Article  PubMed  Google Scholar 

  12. Cassell EJ. The importance of understanding suffering for clinical ethics. J Clin Ethics. 1991;2(2):81–2.

    CAS  PubMed  Google Scholar 

  13. Cassell EJ. The relief of suffering. Arch Intern Med. 1983;143(3):522–3.

    Article  CAS  PubMed  Google Scholar 

  14. Gaither JR, Goulet JL, Becker WC, Crystal S, Edelman EJ, Gordon K, et al. The association between receipt of guideline-concordant long-term opioid therapy and all-cause mortality. J Gen Intern Med. 2016;31(5):492–501.

    Article  PubMed  Google Scholar 

  15. Aronoff GM. What do we know about the pathophysiology of chronic pain? Implications for treatment considerations. Med Clin N Am. 2016;100(1):31–42.

    Article  PubMed  Google Scholar 

  16. Yarnitsky D, Dahan A. Endogenous pain modulation: from humans to animals and back. Anesthesiology. 2015;122(4):734–5.

    Article  PubMed  Google Scholar 

  17. Heinricher MM, Maire JJ, Lee D, Nalwalk JW, Hough LB. Physiological basis for inhibition of morphine and improgan antinociception by CC12, a P450 epoxygenase inhibitor. J Neurophysiol. 2010;104(6):3222–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Heinricher MM, Tavares I, Leith JL, Lumb BM. Descending control of nociception: specificity, recruitment and plasticity. Brain Res Rev. 2009;60(1):214–25.

    Article  CAS  PubMed  Google Scholar 

  19. Mase H, Sakai A, Sakamoto A, Suzuki H. A subset of mu-opioid receptor-expressing cells in the rostral ventromedial medulla contribute to thermal hyperalgesia in experimental neuropathic pain. Neurosci Res. 2011;70(1):35–43.

    Article  CAS  PubMed  Google Scholar 

  20. Vanderah TW, Suenaga NM, Ossipov MH, Malan Jr TP, Lai J, Porreca F. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci Off J Soc Neurosci. 2001;21(1):279–86.

    CAS  Google Scholar 

  21. Kincaid W, Neubert MJ, Xu M, Kim CJ, Heinricher MM. Role for medullary pain facilitating neurons in secondary thermal hyperalgesia. J Neurophysiol. 2006;95(1):33–41.

    Article  PubMed  Google Scholar 

  22. Schepers RJ, Mahoney JL, Shippenberg TS. Inflammation-induced changes in rostral ventromedial medulla mu and kappa opioid receptor mediated antinociception. Pain. 2008;136(3):320–30.

    Article  CAS  PubMed  Google Scholar 

  23. Upadhyay J, Maleki N, Potter J, Elman I, Rudrauf D, Knudsen J, et al. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Brain. 2010;133(Pt 7):2098–114.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Upadhyay J, Anderson J, Baumgartner R, Coimbra A, Schwarz AJ, Pendse G, et al. Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine. NeuroImage. 2012;59(4):3762–73.

    Article  CAS  PubMed  Google Scholar 

  25. Aoki Y, Mizoguchi H, Watanabe C, Takeda K, Sakurada T, Sakurada S. Potential involvement of mu-opioid receptor dysregulation on the reduced antinociception of morphine in the inflammatory pain state in mice. J Pharmacol Sci. 2014;124(2):258–66.

    Article  CAS  PubMed  Google Scholar 

  26. Mantyh PW. Bone cancer pain: from mechanism to therapy. Curr Opin Support Palliat Care. 2014;8(2):83–90.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Jimenez-Andrade JM, Bloom AP, Stake JI, Mantyh WG, Taylor RN, Freeman KT, et al. Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci Off J Soc Neurosci. 2010;30(44):14649–56.

    Article  CAS  Google Scholar 

  28. Lechner B, Chow S, Chow R, Zhang L, Tsao M, Danjoux C, et al. The incidence of neuropathic pain in bone metastases patients referred for palliative radiotherapy. Radiother Oncol. 2016;118(3):557–61.

    Article  PubMed  Google Scholar 

  29. Karshikoff B, Jensen KB, Kosek E, Kalpouzos G, Soop A, Ingvar M, et al. Why sickness hurts: a central mechanism for pain induced by peripheral inflammation. Brain Behav Immun. 2016.

  30. Hannestad J, Gallezot JD, Schafbauer T, Lim K, Kloczynski T, Morris ED, et al. Endotoxin-induced systemic inflammation activates microglia: [(1)(1)C]PBR28 positron emission tomography in nonhuman primates. NeuroImage. 2012;63(1):232–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ren K. Emerging role of astroglia in pain hypersensitivity. Jpn Dent Sci Rev. 2010;46(1):86.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med. 2010;16(11):1267–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Caraceni A, Zecca E, Martini C, Pigni A, Bracchi P. Gabapentin for breakthrough pain due to bone metastases. Palliat Med. 2008;22(4):392–3.

    Article  CAS  PubMed  Google Scholar 

  34. Caraceni A, Zecca E, Bonezzi C, Arcuri E, Yaya Tur R, Maltoni M, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(14):2909–17.

    Article  CAS  Google Scholar 

  35. Lu Y, Westlund KN. Gabapentin attenuates nociceptive behaviors in an acute arthritis model in rats. J Pharmacol Exp Ther. 1999;290(1):214–9.

    CAS  PubMed  Google Scholar 

  36. Yang JL, Xu B, Li SS, Zhang WS, Xu H, Deng XM, et al. Gabapentin reduces CX3CL1 signaling and blocks spinal microglial activation in monoarthritic rats. Mol Brain. 2012;5:18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Martikainen IK, Pecina M, Love TM, Nuechterlein EB, Cummiford CM, Green CR, et al. Alterations in endogenous opioid functional measures in chronic back pain. J Neurosci Off J Soc Neurosci. 2013;33(37):14729–37.

    Article  CAS  Google Scholar 

  38. Stohler CS, Kowalski CJ. Spatial and temporal summation of sensory and affective dimensions of deep somatic pain. Pain. 1999;79(2–3):165–73.

    Article  CAS  PubMed  Google Scholar 

  39. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science. 2001;293(5528):311–5.

    Article  CAS  PubMed  Google Scholar 

  40. Lopez-de-Uralde-Villanueva I, Beltran-Alacreu H, Fernandez-Carnero J, Kindelan-Calvo P, La Touche R. Widespread pressure pain hyperalgesia in chronic nonspecific neck pain with neuropathic features: a descriptive cross-sectional study. Pain Physician. 2016;19(2):77–88.

    PubMed  Google Scholar 

  41. Lopez-de-Uralde-Villanueva I, Beltran-Alacreu H, Fernandez-Carnero J, Gil-Martinez A, La Touche R. Differences in neural mechanosensitivity between patients with chronic nonspecific neck pain with and without neuropathic features. A descriptive cross-sectional study. Pain Med. 2016;17(1):136–48.

    PubMed  Google Scholar 

  42. Bruehl S, Burns JW, Passik SD, Gupta R, Buvanendran A, Chont M, et al. The contribution of differential opioid responsiveness to identification of opioid risk in chronic pain patients. J Pain. 2015;16(7):666–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Baliki MN, Petre B, Torbey S, Herrmann KM, Huang L, Schnitzer TJ, et al. Corticostriatal functional connectivity predicts transition to chronic back pain. Nat Neurosci. 2012;15(8):1117–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron. 2012;73(4):638–52.

    Article  CAS  Google Scholar 

  45. Backonja M, Woolf CJ. Future directions in neuropathic pain therapy: closing the translational loop. Oncologist. 2010;15 Suppl 2:24–9.

    Article  CAS  PubMed  Google Scholar 

  46. Edwards RR, Dworkin RH, Turk DC, Angst MS, Dionne R, Freeman R, et al. Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain. 2016.

  47. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–80.

    Article  CAS  PubMed  Google Scholar 

  48. Koltzenburg M, Pokorny R, Gasser UE, Richarz U. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain. 2006;126(1–3):165–74.

    Article  CAS  PubMed  Google Scholar 

  49. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet. 1995;345(8965):1616–9.

    Article  CAS  PubMed  Google Scholar 

  50. Kringel D, Ultsch A, Zimmermann M, Jansen JP, Ilias W, Freynhagen R, et al. Emergent biomarker derived from next-generation sequencing to identify pain patients requiring uncommonly high opioid doses. The pharmacogenomics journal. 2016.

  51. Zhang Y, Ahmed S, Vo T, St Hilaire K, Houghton M, Cohen AS, et al. Increased pain sensitivity in chronic pain subjects on opioid therapy: a cross-sectional study using quantitative sensory testing. Pain Med. 2015;16(5):911–22.

    Article  CAS  PubMed  Google Scholar 

  52. Kirkpatrick DR, McEntire DM, Hambsch ZJ, Kerfeld MJ, Smith TA, Reisbig MD, et al. Therapeutic basis of clinical pain modulation. Clin Transl Sci. 2015;8(6):848–56.

    Article  PubMed  Google Scholar 

  53. Fletcher D, Martinez V. Opioid-induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis. Br J Anaesth. 2014;112(6):991–1004.

    Article  CAS  PubMed  Google Scholar 

  54. Chen L, Malarick C, Seefeld L, Wang S, Houghton M, Mao J. Altered quantitative sensory testing outcome in subjects with opioid therapy. Pain. 2009;143(1–2):65–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Wang H, Akbar M, Weinsheimer N, Gantz S, Schiltenwolf M. Longitudinal observation of changes in pain sensitivity during opioid tapering in patients with chronic low-back pain. Pain Med. 2011;12(12):1720–6.

    Article  PubMed  Google Scholar 

  56. Carullo V, Fitz-James I, Delphin E. Opioid-induced hyperalgesia: a diagnostic dilemma. J Pain Palliat Care Pharmacother. 2015;29(4):378–84.

    Article  PubMed  Google Scholar 

  57. Mao J. Clinical diagnosis of opioid-induced hyperalgesia. Reg Anesth Pain Med. 2015;40(6):663–4.

    Article  PubMed  Google Scholar 

  58. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145–61.

    PubMed  Google Scholar 

  59. Grace PM, Ramos KM, Rodgers KM, Wang X, Hutchinson MR, Lewis MT, et al. Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelae. Neuroscience. 2014;280:299–317.

    Article  CAS  PubMed  Google Scholar 

  60. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. TheScientificWorldJOURNAL. 2007;7:98–111.

    Article  PubMed  Google Scholar 

  61. Hutchinson MR, Coats BD, Lewis SS, Zhang Y, Sprunger DB, Rezvani N, et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun. 2008;22(8):1178–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011;63(3):772–810.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Lee C, Lee HW, Kim JN. Effect of oral pregabalin on opioid-induced hyperalgesia in patients undergoing laparo-endoscopic single-site urologic surgery. Korean J Anesthesiol. 2013;64(1):19–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Juni A, Klein G, Pintar JE, Kest B. Nociception increases during opioid infusion in opioid receptor triple knock-out mice. Neuroscience. 2007;147(2):439–44.

    Article  CAS  PubMed  Google Scholar 

  65. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24(1):83–95.

    Article  CAS  PubMed  Google Scholar 

  66. Blondell RD, Ashrafioun L, Dambra CM, Foschio EM, Zielinski AL, Salcedo DM. A clinical trial comparing tapering doses of buprenorphine with steady doses for chronic pain and co-existent opioid addiction. J Addict Med. 2010;4(3):140–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Vorobeychik Y, Chen L, Bush MC, Mao J. Improved opioid analgesic effect following opioid dose reduction. Pain Med. 2008;9(6):724–7.

    Article  PubMed  Google Scholar 

  68. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010;13(5):401–35.

    PubMed  Google Scholar 

  69. Manchikanti L, Vallejo R, Manchikanti KN, Benyamin RM, Datta S, Christo PJ. Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician. 2011;14(2):E133–56.

    PubMed  Google Scholar 

  70. Manchikanti L, Singh V, Cash KA, Pampati V, Damron KS, Boswell MV. A randomized, controlled, double-blind trial of fluoroscopic caudal epidural injections in the treatment of lumbar disc herniation and radiculitis. Spine. 2011;36(23):1897–905.

    Article  PubMed  Google Scholar 

  71. Corder G, Doolen S, Donahue RR, Winter MK, Jutras BL, He Y, et al. Constitutive mu-opioid receptor activity leads to long-term endogenous analgesia and dependence. Science. 2013;341(6152):1394–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Pereira MP, Donahue RR, Dahl JB, Werner M, Taylor BK, Werner MU. Endogenous opioid-masked latent pain sensitization: studies from mouse to human. PLoS One. 2015;10(8), e0134441.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 2001;15(3):598–611.

    Article  CAS  PubMed  Google Scholar 

  74. Connor M, Traynor J. Constitutively active mu-opioid receptors. Methods Enzymol. 2010;484:445–69.

    Article  CAS  PubMed  Google Scholar 

  75. Walwyn W, Evans CJ, Hales TG. Beta-arrestin2 and c-Src regulate the constitutive activity and recycling of mu opioid receptors in dorsal root ganglion neurons. J Neurosci Off J Soc Neurosci. 2007;27(19):5092–104.

    Article  CAS  Google Scholar 

  76. Ellis A, Grace PM, Wieseler J, Favret J, Springer K, Skarda B, et al. Morphine amplifies mechanical allodynia via TLR4 in a rat model of spinal cord injury. Brain Behav Immun. 2016.

  77. Grace PM, Strand KA, Galer EL, Urban DJ, Wang X, Baratta MV, et al. Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation. Proc Natl Acad Sci U S A. 2016;113(24):E3441–50.

    Article  CAS  PubMed  Google Scholar 

  78. Wasan AD, Michna E, Edwards RR, Katz JN, Nedeljkovic SS, Dolman AJ, et al. Psychiatric comorbidity is associated prospectively with diminished opioid analgesia and increased opioid misuse in patients with chronic low back pain. Anesthesiology. 2015;123(4):861–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Jamison RN, Edwards RR, Liu X, Ross EL, Michna E, Warnick M, et al. Relationship of negative affect and outcome of an opioid therapy trial among low back pain patients. Pain Pract. 2013;13(3):173–81.

    Article  PubMed  Google Scholar 

  80. Edwards RR, Wasan AD, Michna E, Greenbaum S, Ross E, Jamison RN. Elevated pain sensitivity in chronic pain patients at risk for opioid misuse. J Pain. 2011;12(9):953–63.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Edwards RR, Dolman AJ, Michna E, Katz JN, Nedeljkovic SS, Janfaza D, et al. Changes in pain sensitivity and pain modulation during oral opioid treatment: the impact of negative affect. Pain Med. 2016.

  82. •Scherrer JF, Salas J, Sullivan MD, Schneider FD, Bucholz KK, Burroughs T, et al. The influence of prescription opioid use duration and dose on development of treatment resistant depression. Prev Med. 2016. This is a new findings associated with opioid therapy.

  83. Scherrer JF, Salas J, Bucholz KK, Schneider FD, Burroughs T, Copeland LA, et al. New depression diagnosis following prescription of codeine, hydrocodone or oxycodone. Pharmacoepidemiol Drug Saf. 2016;25(5):560–8.

    Article  CAS  PubMed  Google Scholar 

  84. Scherrer JF, Salas J, Copeland LA, Stock EM, Schneider FD, Sullivan M, et al. Increased risk of depression recurrence after initiation of prescription opioids in noncancer pain patients. J Pain. 2016;17(4):473–82.

    Article  PubMed  Google Scholar 

  85. Scherrer JF, Salas J, Lustman PJ, Burge S, Schneider FD. Residency Research Network of Texas I. Change in opioid dose and change in depression in a longitudinal primary care patient cohort. Pain. 2015;156(2):348–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Scherrer JF, Svrakic DM, Freedland KE, Chrusciel T, Balasubramanian S, Bucholz KK, et al. Prescription opioid analgesics increase the risk of depression. J Gen Intern Med. 2014;29(3):491–9.

    Article  PubMed  Google Scholar 

  87. Chiou CS, Chen CC, Tsai TC, Huang CC, Chou D, Hsu KS. Alleviating bone cancer-induced mechanical hypersensitivity by inhibiting neuronal activity in the anterior cingulate cortex. Anesthesiology. 2016.

  88. Barthas F, Sellmeijer J, Hugel S, Waltisperger E, Barrot M, Yalcin I. The anterior cingulate cortex is a critical hub for pain-induced depression. Biol Psychiatry. 2015;77(3):236–45.

    Article  PubMed  Google Scholar 

  89. Yalcin I, Barrot M. The anxiodepressive comorbidity in chronic pain. Curr Opin Anaesthesiol. 2014;27(5):520–7.

    Article  CAS  PubMed  Google Scholar 

  90. Yalcin I, Barthas F, Barrot M. Emotional consequences of neuropathic pain: insight from preclinical studies. Neurosci Biobehav Rev. 2014;47:154–64.

    Article  PubMed  Google Scholar 

  91. Correa D, Farney RJ, Chung F, Prasad A, Lam D, Wong J. Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg. 2015;120(6):1273–85.

    Article  CAS  PubMed  Google Scholar 

  92. Walker JM, Farney RJ, Rhondeau SM, Boyle KM, Valentine K, Cloward TV, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med. 2007;3(5):455–61.

    PubMed  PubMed Central  Google Scholar 

  93. ••Webster LR, Choi Y, Desai H, Webster L, Grant BJ. Sleep-disordered breathing and chronic opioid therapy. Pain Med. 2008;9(4):425–32. Most opioid deaths occur at night and it may be related to the high risk of central sleep apnea that occurs with opioids.

    Article  PubMed  Google Scholar 

  94. Mogri M, Desai H, Webster L, Grant BJ, Mador MJ. Hypoxemia in patients on chronic opiate therapy with and without sleep apnea. Sleep Breath. 2009;13(1):49–57.

    Article  PubMed  Google Scholar 

  95. Sharkey KM, Kurth ME, Anderson BJ, Corso RP, Millman RP, Stein MD. Obstructive sleep apnea is more common than central sleep apnea in methadone maintenance patients with subjective sleep complaints. Drug Alcohol Depend. 2010;108(1–2):77–83.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Wang D, Teichtahl H, Drummer O, Goodman C, Cherry G, Cunnington D, et al. Central sleep apnea in stable methadone maintenance treatment patients. Chest. 2005;128(3):1348–56.

    Article  PubMed  Google Scholar 

  97. Emery MJ, Groves CC, Kruse TN, Shi C, Terman GW. Ventilation and the response to hypercapnia after morphine in opioid-naive and opioid-tolerant rats. Anesthesiology. 2016;124(4):945–57.

    Article  CAS  PubMed  Google Scholar 

  98. Feldman JL, Del Negro CA. Looking for inspiration: new perspectives on respiratory rhythm. Nat Rev Neurosci. 2006;7(3):232–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Lalley PM. Opioidergic and dopaminergic modulation of respiration. Respir Physiol Neurobiol. 2008;164(1–2):160–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Pattinson KT, Mitsis GD, Harvey AK, Jbabdi S, Dirckx S, Mayhew SD, et al. Determination of the human brainstem respiratory control network and its cortical connections in vivo using functional and structural imaging. NeuroImage. 2009;44(2):295–305.

    Article  PubMed  Google Scholar 

  101. Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747–58.

    Article  CAS  PubMed  Google Scholar 

  102. Reddy R, Adamo D, Kufel T, Porhomayon J, El-Solh AA. Treatment of opioid-related central sleep apnea with positive airway pressure: a systematic review. J Opioid Manag. 2014;10(1):57–62.

    Article  PubMed  Google Scholar 

  103. Farney RJ, Walker JM, Boyle KM, Cloward TV, Shilling KC. Adaptive servoventilation (ASV) in patients with sleep disordered breathing associated with chronic opioid medications for non-malignant pain. J Clin Sleep Med. 2008;4(4):311–9.

    PubMed  PubMed Central  Google Scholar 

  104. Javaheri S, Malik A, Smith J, Chung E. Adaptive pressure support servoventilation: a novel treatment for sleep apnea associated with use of opioids. J Clin Sleep Med. 2008;4(4):305–10.

    PubMed  PubMed Central  Google Scholar 

  105. Wang D, Lintzeris N, Leung S, Haber PS, Yee BJ, Grunstein RR. Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report. Eur Respir J. 2015;46(4):1202–5.

    Article  PubMed  Google Scholar 

  106. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3(4):223–32.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Baldacchino A, Balfour DJ, Passetti F, Humphris G, Matthews K. Neuropsychological consequences of chronic opioid use: a quantitative review and meta-analysis. Neurosci Biobehav Rev. 2012;36(9):2056–68.

    Article  CAS  PubMed  Google Scholar 

  108. Sjogren P, Olsen AK, Thomsen AB, Dalberg J. Neuropsychological performance in cancer patients: the role of oral opioids, pain and performance status. Pain. 2000;86(3):237–45.

    Article  CAS  PubMed  Google Scholar 

  109. Brown RT, Zuelsdorff M, Fleming M. Adverse effects and cognitive function among primary care patients taking opioids for chronic nonmalignant pain. J Opioid Manag. 2006;2(3):137–46.

    PubMed  Google Scholar 

  110. Tassain V, Attal N, Fletcher D, Brasseur L, Degieux P, Chauvin M, et al. Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain. Pain. 2003;104(1–2):389–400.

    Article  CAS  PubMed  Google Scholar 

  111. Kurita GP, Pimenta CA, Nobre MR. Opioids and cognition in patients with chronic pain: a systematic review. Rev Assoc Med Bras. 2008;54(6):529–36.

    Article  PubMed  Google Scholar 

  112. Kurita GP, Lundorff L, Pimenta CA, Sjogren P. The cognitive effects of opioids in cancer: a systematic review. Supportive Care Cancer. 2009;17(1):11–21.

    Article  Google Scholar 

  113. Sjogren P, Banning A. Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain. 1989;39(1):5–11.

    Article  CAS  PubMed  Google Scholar 

  114. Hojsted J, Kurita GP, Kendall S, Lundorff L, de Mattos Pimenta CA, Sjogren P. Non-analgesic effects of opioids: the cognitive effects of opioids in chronic pain of malignant and non-malignant origin. An update. Curr Pharm Des. 2012;18(37):6116–22.

    Article  PubMed  Google Scholar 

  115. Kurita GP, de Mattos Pimenta CA, Braga PE, Frich L, Jorgensen MM, Nielsen PR, et al. Cognitive function in patients with chronic pain treated with opioids: characteristics and associated factors. Acta Anaesthesiol Scand. 2012;56(10):1257–66.

    Article  CAS  PubMed  Google Scholar 

  116. Schiltenwolf M, Akbar M, Hug A, Pfuller U, Gantz S, Neubauer E, et al. Evidence of specific cognitive deficits in patients with chronic low back pain under long-term substitution treatment of opioids. Pain Physician. 2014;17(1):9–20.

    PubMed  Google Scholar 

  117. Kurita GP, Sjogren P, Ekholm O, Kaasa S, Loge JH, Poviloniene I, et al. Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(10):1297–303.

    Article  Google Scholar 

  118. Kurita GP, Ekholm O, Kaasa S, Klepstad P, Skorpen F, Sjogren P. Genetic variation and cognitive dysfunction in opioid-treated patients with cancer. Brain Behav. 2016;6(7), e00471.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Khodayari-Rostamabad A, Olesen SS, Graversen C, Malver LP, Kurita GP, Sjogren P, et al. Disruption of cortical connectivity during remifentanil administration is associated with cognitive impairment but not with analgesia. Anesthesiology. 2015;122(1):140–9.

    Article  CAS  PubMed  Google Scholar 

  120. Bruera E, El Osta B, Valero V, Driver LC, Pei BL, Shen L, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(23):3475–81.

    Article  CAS  Google Scholar 

  121. Bruera E, Strasser F, Shen L, Palmer JL, Willey J, Driver LC, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manag. 2003;26(5):1049–54.

    Article  CAS  Google Scholar 

  122. Khojainova N, Santiago-Palma J, Kornick C, Breitbart W, Gonzales GR. Olanzapine in the management of cancer pain. J Pain Symptom Manag. 2002;23(4):346–50.

    Article  CAS  Google Scholar 

  123. Kamboj SK, Tookman A, Jones L, Curran HV. The effects of immediate-release morphine on cognitive functioning in patients receiving chronic opioid therapy in palliative care. Pain. 2005;117(3):388–95.

    Article  CAS  PubMed  Google Scholar 

  124. Gudin JA, Laitman A, Nalamachu S. Opioid related endocrinopathy. Pain Med. 2015;16 Suppl 1:S9–15.

    Article  PubMed  Google Scholar 

  125. Aloisi AM, Aurilio C, Bachiocco V, Biasi G, Fiorenzani P, Pace MC, et al. Endocrine consequences of opioid therapy. Psychoneuroendocrinology. 2009;34 Suppl 1:S162–8.

    Article  CAS  PubMed  Google Scholar 

  126. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100(4):851–8.

    Article  CAS  PubMed  Google Scholar 

  127. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9(1):28–36.

    Article  CAS  PubMed  Google Scholar 

  128. Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J Pain. 2006;7(12):901–7.

    Article  CAS  PubMed  Google Scholar 

  129. Rubinstein A, Carpenter DM. Elucidating risk factors for androgen deficiency associated with daily opioid use. Am J Med. 2014;127(12):1195–201.

    Article  CAS  PubMed  Google Scholar 

  130. Elliott JA, Horton E, Fibuch EE. The endocrine effects of long-term oral opioid therapy: a case report and review of the literature. J Opioid Manag. 2011;7(2):145–54.

    PubMed  Google Scholar 

  131. Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009;25(2):170–5.

    Article  PubMed  Google Scholar 

  132. Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin N Am. 2007;36(2):333–48.

    Article  CAS  Google Scholar 

  133. Aloisi AM, Ceccarelli I, Fiorenzani P, Maddalena M, Rossi A, Tomei V, et al. Aromatase and 5-alpha reductase gene expression: modulation by pain and morphine treatment in male rats. Mol Pain. 2010;6:69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ. American Association of Clinical E. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. Endocr Pract. 2002;8(6):440–56.

    PubMed  Google Scholar 

  135. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl. 2009;30(1):1–9.

    Article  PubMed  Google Scholar 

  136. Yeap BB, Grossmann M, McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ, et al. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Med J Aust. 2016;205(4):173–8.

    Article  PubMed  Google Scholar 

  137. Rajagopal A, Bruera ED. Improvement in sexual function after reduction of chronic high-dose opioid medication in a cancer survivor. Pain Med. 2003;4(4):379–83.

    Article  PubMed  Google Scholar 

  138. Aloisi AM, Ceccarelli I, Carlucci M, Suman A, Sindaco G, Mameli S, et al. Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients. Reprod Biol Endocrinol. 2011;9:26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Basaria S, Travison TG, Alford D, Knapp PE, Teeter K, Cahalan C, et al. Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial. Pain. 2015;156(2):280–8.

    Article  CAS  PubMed  Google Scholar 

  140. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male. 2012;15(1):14–21.

    Article  CAS  PubMed  Google Scholar 

  141. Huang G, Travison T, Maggio M, Edwards RR, Basaria S. Effects of testosterone replacement on metabolic and inflammatory markers in men with opioid-induced androgen deficiency. Clin Endocrinol. 2016;85(2):232–8.

    Article  CAS  Google Scholar 

  142. Li L, Setoguchi S, Cabral H, Jick S. Opioid use for noncancer pain and risk of myocardial infarction amongst adults. J Intern Med. 2013;273(5):511–26.

    Article  CAS  PubMed  Google Scholar 

  143. Smith HS, Elliott JA. Opioid-induced androgen deficiency (OPIAD). Pain Physician. 2012;15(3 Suppl):ES145–56.

    PubMed  Google Scholar 

  144. Aparasu RR, Chatterjee S, Chen H. Risk of hospitalization and use of first- versus second-generation antipsychotics among nursing home residents. Psychiatr Serv. 2014;65(6):781–8.

    Article  PubMed  Google Scholar 

  145. Soderberg KC, Laflamme L, Moller J. Newly initiated opioid treatment and the risk of fall-related injuries. A nationwide, register-based, case-crossover study in Sweden. CNS Drugs. 2013;27(2):155–61.

    Article  CAS  PubMed  Google Scholar 

  146. Acurcio FA, Moura CS, Bernatsky S, Bessette L, Rahme E. Opioid use and risk of nonvertebral fractures in adults with rheumatoid arthritis: a nested case–control study using administrative databases. Arthritis Rheum. 2016;68(1):83–91.

    Article  CAS  Google Scholar 

  147. Hirst A, Knight C, Hirst M, Dunlop W, Akehurst R. Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine. Eur J Health Econ. 2016;17(2):217–27.

    Article  PubMed  Google Scholar 

  148. Saunders KW, Dunn KM, Merrill JO, Sullivan M, Weisner C, Braden JB, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med. 2010;25(4):310–5.

    Article  PubMed  PubMed Central  Google Scholar 

  149. Li L, Setoguchi S, Cabral H, Jick S. Opioid use for noncancer pain and risk of fracture in adults: a nested case–control study using the general practice research database. Am J Epidemiol. 2013;178(4):559–69.

    Article  PubMed  Google Scholar 

  150. Coluzzi F, Pergolizzi J, Raffa RB, Mattia C. The unsolved case of “bone-impairing analgesics”: the endocrine effects of opioids on bone metabolism. Ther Clin Risk Manag. 2015;11:515–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Shanmugam VK, Fernandez SJ, Evans KK, McNish S, Banerjee AN, Couch KS, et al. Postoperative wound dehiscence: predictors and associations. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair. Society. 2015;23(2):184–90.

    Google Scholar 

  152. Kuchler S, Wolf NB, Heilmann S, Weindl G, Helfmann J, Yahya MM, et al. 3D-wound healing model: influence of morphine and solid lipid nanoparticles. J Biotechnol. 2010;148(1):24–30.

    Article  CAS  PubMed  Google Scholar 

  153. Martin JL, Koodie L, Krishnan AG, Charboneau R, Barke RA, Roy S. Chronic morphine administration delays wound healing by inhibiting immune cell recruitment to the wound site. Am J Pathol. 2010;176(2):786–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Martin JL, Charboneau R, Barke RA, Roy S. Chronic morphine treatment inhibits LPS-induced angiogenesis: implications in wound healing. Cell Immunol. 2010;265(2):139–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Immonen JA, Zagon IS, Lewis GS, McLaughlin PJ. Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats. Exp Biol Med. 2013;238(10):1127–35.

    Article  CAS  Google Scholar 

  156. McLaughlin PJ, Immonen JA, Zagon IS. Topical naltrexone accelerates full-thickness wound closure in type 1 diabetic rats by stimulating angiogenesis. Exp Biol Med. 2013;238(7):733–43.

    Article  CAS  Google Scholar 

  157. Chrastil J, Sampson C, Jones KB, Higgins TF. Evaluating the affect and reversibility of opioid-induced androgen deficiency in an orthopaedic animal fracture model. Clin Orthop Relat Res. 2014;472(6):1964–71.

    Article  PubMed  PubMed Central  Google Scholar 

  158. Matziolis G, Rau HM, Klever P, Erli HJ, Paar O. Modification of human osteoblasts by various analgesics. Unfallchirurg. 2002;105(6):527–31.

    Article  CAS  PubMed  Google Scholar 

  159. Ozkan D, Seker D, Ergil J, Yalcindag A, Han U, Ginis Z, et al. The effects of tramadol infiltration on wound healing in rats. Acta Chir Belg. 2013;113(6):434–8.

    CAS  PubMed  Google Scholar 

  160. Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002–12. Health Aff. 2016;35(5):832–7.

    Article  Google Scholar 

  161. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther. 2004;11(5):354–65.

    Article  PubMed  Google Scholar 

  162. Tubaro E, Borelli G, Croce C, Cavallo G, Santiangeli C. Effect of morphine on resistance to infection. J Infect Dis. 1983;148(4):656–66.

    Article  CAS  PubMed  Google Scholar 

  163. Wang J, Barke RA, Charboneau R, Roy S. Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J Immunol. 2005;174(1):426–34.

    Article  CAS  PubMed  Google Scholar 

  164. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Von Korff M, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case–control study. J Am Geriatr Soc. 2011;59(10):1899–907.

    Article  PubMed  PubMed Central  Google Scholar 

  165. Yeager MP, Colacchio TA, Yu CT, Hildebrandt L, Howell AL, Weiss J, et al. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology. 1995;83(3):500–8.

    Article  CAS  PubMed  Google Scholar 

  166. Hendrickson M, Shelby J, Sullivan JJ, Saffle JR. Naloxone inhibits the in vivo immunosuppressive effects of morphine and thermal injury in mice. J Burn Care Rehabil. 1989;10(6):494–8.

    Article  CAS  PubMed  Google Scholar 

  167. Ballard KA, Pellegrino TC, Alonzo NC, Nugent AL, Bayer BM. Enhanced immune sensitivity to stress following chronic morphine exposure. J Neuroimmune Pharmacol. 2006;1(1):106–15.

    Article  PubMed  Google Scholar 

  168. Bryant HU, Roudebush RE. Suppressive effects of morphine pellet implants on in vivo parameters of immune function. J Pharmacol Exp Ther. 1990;255(2):410–4.

    CAS  PubMed  Google Scholar 

  169. Ninkovic J, Roy S. Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids. 2013;45(1):9–24.

    Article  CAS  PubMed  Google Scholar 

  170. Banerjee S, Sindberg G, Wang F, Meng J, Sharma U, Zhang L, et al. Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation. Mucosal Immunol. 2016.

  171. Meng J, Banerjee S, Li D, Sindberg GM, Wang F, Ma J, et al. Opioid exacerbation of gram-positive sepsis, induced by gut microbial modulation, is rescued by IL-17A neutralization. Sci Rep. 2015;5:10918.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Liu B, Liu X, Tang SJ. Interactions of opioids and HIV infection in the pathogenesis of chronic pain. Front Microbiol. 2016;7:103.

    PubMed  PubMed Central  Google Scholar 

  173. El-Hage N, Rodriguez M, Dever SM, Masvekar RR, Gewirtz DA, Shacka JJ. HIV-1 and morphine regulation of autophagy in microglia: limited interactions in the context of HIV-1 infection and opioid abuse. J Virol. 2015;89(2):1024–35.

    Article  CAS  PubMed  Google Scholar 

  174. Liang B, Jiang J, Pan P, Chen R, Zhuang D, Zhao F, et al. Morphine increases lamivudine- and nevirapine-induced human immunodeficiency virus-1 drug-resistant mutations in vitro. Microb Drug Resist. 2016.

  175. Von Korff M, Merrill JO, Rutter CM, Sullivan M, Campbell CI, Weisner C. Time-scheduled vs. pain-contingent opioid dosing in chronic opioid therapy. Pain. 2011;152(6):1256–62.

    Article  Google Scholar 

  176. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. Pain Physician. 2012;15(3 Suppl):S67–116.

    PubMed  Google Scholar 

  177. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I--evidence assessment. Pain Physician. 2012;15(3 Suppl):S1–65.

    PubMed  Google Scholar 

  178. Koyyalagunta D, Bruera E, Solanki DR, Nouri KH, Burton AW, Toro MP, et al. A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician. 2012;15(3 Suppl):ES39–58.

    PubMed  Google Scholar 

  179. Drewes AM, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L, et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol. 2013;75(1):60–78.

    Article  CAS  PubMed  Google Scholar 

  180. Leider HL, Dhaliwal J, Davis EJ, Kulakodlu M, Buikema AR. Healthcare costs and nonadherence among chronic opioid users. Am J Manag Care. 2011;17(1):32–40.

    PubMed  Google Scholar 

  181. Hakkinen M, Launiainen T, Vuori E, Ojanpera I. Comparison of fatal poisonings by prescription opioids. Forensic Sci Int. 2012;222(1–3):327–31.

    Article  CAS  PubMed  Google Scholar 

  182. Coben JH, Davis SM, Furbee PM, Sikora RD, Tillotson RD, Bossarte RM. Hospitalizations for poisoning by prescription opioids, sedatives, and tranquilizers. Am J Prev Med. 2010;38(5):517–24.

    Article  PubMed  Google Scholar 

  183. Centers for Disease C, Prevention. Emergency department visits involving nonmedical use of selected prescription drugs - United States, 2004–2008. MMWR Morb Mortal Wkly Rep. 2010;59(23):705–9.

    Google Scholar 

  184. Paulozzi LJ, Logan JE, Hall AJ, McKinstry E, Kaplan JA, Crosby AE. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction. 2009;104(9):1541–8.

    Article  PubMed  Google Scholar 

  185. Jonsson T, Christrup LL, Hojsted J, Villesen HH, Albjerg TH, Ravn-Nielsen LV, et al. Symptoms and side effects in chronic non-cancer pain: patient report vs. systematic assessment. Acta Anaesthesiol Scand. 2011;55(1):69–74.

    Article  CAS  PubMed  Google Scholar 

  186. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;1, CD006605.

    Google Scholar 

  187. Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin. 2005;21(10):1555–68.

    Article  CAS  PubMed  Google Scholar 

  188. Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006;125(1–2):172–9.

    Article  CAS  PubMed  Google Scholar 

  189. Sjogren P, Gronbaek M, Peuckmann V, Ekholm O. A population-based cohort study on chronic pain: the role of opioids. Clin J Pain. 2010;26(9):763–9.

    Article  PubMed  Google Scholar 

  190. Carmichael AN, Morgan L, Del Fabbro E. Identifying and assessing the risk of opioid abuse in patients with cancer: an integrative review. Subst Abuse Rehabil. 2016;7:71–9.

    PubMed  PubMed Central  Google Scholar 

  191. Trang T, Al-Hasani R, Salvemini D, Salter MW, Gutstein H, Cahill CM. Pain and poppies: the good, the bad, and the ugly of opioid analgesics. J Neurosci Off J Soc Neurosci. 2015;35(41):13879–88.

    Article  CAS  Google Scholar 

  192. Bannister K. Opioid-induced hyperalgesia: where are we now? Curr Opin Support Palliat Care. 2015;9(2):116–21.

    Article  PubMed  Google Scholar 

  193. Stoicea N, Russell D, Weidner G, Durda M, Joseph NC, Yu J, et al. Opioid-induced hyperalgesia in chronic pain patients and the mitigating effects of gabapentin. Front Pharmacol. 2015;6:104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  194. Coluzzi F, Taylor Jr R, Pergolizzi Jr JV, Mattia C, Raffa RB. Good clinical practice guide for opioids in pain management: the three Ts - titration (trial), tweaking (tailoring), transition (tapering). Braz J Anesthesiol. 2016;66(3):310–7.

    Article  PubMed  Google Scholar 

  195. Bihel F. Opioid adjuvant strategy: improving opioid effectiveness. Future Med Chem. 2016;8(3):339–54.

    Article  CAS  PubMed  Google Scholar 

  196. Walsh TD, Saunders CM. Oral morphine for relief of chronic pain from cancer. N Engl J Med. 1981;305(23):1417–8.

    CAS  PubMed  Google Scholar 

  197. Saunders C. Care of the dying-4. Control of pain in terminal cancer. Nurs Times. 1976;72(29):1133–5.

    CAS  PubMed  Google Scholar 

  198. Saunders C. The treatment of intractable pain in terminal cancer. Proc R Soc Med. 1963;56:195–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  199. Saunders C. An individual approach to the relief of pain. In: People and cancer. London: The British Council; 1970. p. 34–8.

    Google Scholar 

  200. Saunders C. Current views in pain relief and terminology. In: Swerdlow M, editor. The therapy of pain. Lancaster, UK, 1981.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mellar P. Davis.

Ethics declarations

Conflict of Interest

Mellar P. Davis and Zankhana Mehta declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Palliative Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davis, M.P., Mehta, Z. Opioids and Chronic Pain: Where Is the Balance?. Curr Oncol Rep 18, 71 (2016). https://doi.org/10.1007/s11912-016-0558-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-016-0558-1

Keywords

Navigation